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ABSTRACT
Objectives: It is unclear whether insulin-like growth factor (IGF) function is involved in the
pathophysiology of chronic fatigue syndrome (CFS). Unpublished data and reports in patient
organization newsletters suggest that Acclydine, a food supplement, could be effective in the
treatment of CFS by increasing biologically active IGF1 levels. Here we aimed to measure the
IGF1 and IGF binding protein (IGFBP) 3 status of CFS patients compared to age- and gender-
matched neighborhood controls, and to assess the effect of Acclydine on fatigue severity,
functional impairment, and biologically active IGF1 level (IGFBP3/IGF1 ratio).
Design: A randomized, placebo-controlled, double-blind clinical trial.
Setting: Radboud University Nijmegen Medical Centre, The Netherlands.
Participants: Fifty-seven adult patients who fulfilled the US Centers for Disease Control and
Prevention criteria for CFS. IGF status of 22 CFS patients was compared to that of 22 healthy
age- and gender-matched neighborhood control individuals.
Intervention: Acclydine or placebo for 14 wk.
Outcome measures: Outcomes were fatigue severity (Checklist Individual Strength, subscale
fatigue severity [CIS-fatigue]), functional impairment (Sickness Impact Profile-8 [SIP-8]), and
biologically active IGF1 serum concentrations. Analyses were on an intention-to-treat basis.
Results: There was no difference in IGF status in 22 CFS patients compared to healthy age-
and gender-matched control individuals. Treatment with Acclydine did not result in significant
differences compared with the placebo group on any of the outcome measures: CIS-fatigue
þ1.1 (95% CI 4.4 toþ6.5, p¼0.70), SIP-8þ59.1 (95% CI 201.7 toþ319.8, p¼0.65), and IGFBP3/
IGF1 ratio  0.5 (95% CI  2.8 to þ1.7, p ¼ 0.63).
Conclusion: We found no differences in IGF1 status in CFS patients compared to healthy
matched neighborhood controls. In addition, the results of this clinical trial do not demonstrate
any benefit of Acclydine over placebo in the treatment of CFS.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Chronic fatigue syndrome (CFS) is a medically unexplained
syndrome, characterized by severe disabling fatigue for a
period of at least 6 mo that has led to considerable
impairment in daily functioning [1]. Various accompanying
symptoms may be present, such as headache, joint and muscle
pain, sore throat, and impaired memory and concentration.
Of the many therapeutic interventions that have been
undertaken, so far only cognitive behavioral therapy and
graded exercise therapy have met with success [2].
Neuroendocrinological investigations have tried to eluci-
date the pathophysiology of CFS [3]. As CFS patients and
adult patients with a growth hormone (GH) deﬁciency report
similar symptoms such as fatigue, myalgia, a diminished
sense of well-being, and reduced physical capacity [4,5] and
treatment of GH-deﬁcient adults with GH has measurable
effects on physical function and perception of fatigue [6],
GH status is a focus of this research.. Changes in the GH/
insulin-like growth factor (IGF) 1 axis have been reported in
CFS and fatigue-related disorders such as ﬁbromyalgia [7].
IGF1 studies in CFS patients have yielded conﬂicting results:
low [8,9], normal [10,11], and increased [12] basal IGF1 levels
have been found. Sample size, selection of controls,
appropriateness of matching, and selection of CFS patients
with psychiatric co-morbidity could explain the conﬂicting
results.
Despite the conﬂicting publications concerning IGF1 status
in CFS patients, in recent years there have been reports in
patient organization newsletters that a new food supplement
called Acclydine could be an effective treatment for CFS. The
active ingredient of Acclydine is an alkaloid from Solanum
dulcamara. It has been claimed that Acclydine is effective
because it increases IGF1 concentrations in CFS patients by
stimulating GH releasing hormone and, consequently, GH
secretion. GH is converted to IGF1 in the liver. IGF1 activates
tyrosine kinase and integrin receptors and stimulates intra-
cellular lipid and glycogen synthesis.
Levels of IGF binding proteins (IGFBPs), particularly
IGFBP3, modulate the biological activity of IGF1, and the
ratio of IGFBP3 to IGF1 reﬂects IGF1 biological activity [13].
There are unpublished observations suggesting that Accly-
dine could increase the IGF1 plasma concentrations in
healthy humans and in CFS patients. An 8-wk controlled
trial with Acclydine in combination with amino acid
supplementation in 90 CFS patients has been reported to
have a positive effect [14].
However, there are, to our knowledge, no published peer-
reviewed studies investigating the effect of Acclydine.
Double-blind randomized controlled trials are needed, for
several reasons. First, this food supplement is available on the
Internet without prescription and is thus easily accessible.
Second, although the effects of Acclydine treatment have not
been evaluated thoroughly, there are ongoing studies in other
vulnerable patient categories, such as in cancer patients with
chronic fatigue after treatment, but these studies are not
listed in the international controlled trial registry Current
Controlled Trials (http://www.controlled-trials.com).
For the reasons given above, we assessed the IGFBP3/IGF1
status in patients fulﬁlling the US Centers for Disease Control
and Prevention (CDC) criteria for CFS [1] and in healthy
gender- and age-matched neighborhood controls, to evaluate
whether there are intrinsic differences in IGFBP3/IGF1 status
between the two groups. Furthermore, we investigated the
effect of Acclydine on IGF1 concentration, IGFBP3/IGF1
ratio, and CFS-related symptoms in a well-deﬁned CFS
population using validated outcome measures and a random-
ized double-blind placebo-controlled design.
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Editorial Commentary
Background: Chronic fatigue syndrome is a complicated and poorly
understood illness. People with the condition experience tiredness that
carries on for a long period of time and does not get better with rest.
Other symptoms include sleeping problems, muscle and joint pains,
concentration difficulties, and headaches. The causes of chronic fatigue
syndrome are not known. There is evidence for the effectiveness of
certain behavioral interventions, such as exercise therapy and cognitive
behavioral therapy, in improving certain symptoms. However, some
doctors are concerned that a food supplement called Acclydine, derived
from a plant called Solanum dulcamara, is being used and promoted as a
treatment for chronic fatigue syndrome when there is little evidence
about the efficacy or safety of this supplement.
The researchers here carried out a randomized trial in The Netherlands,
recruiting adult patients who met the internationally accepted criteria for
chronic fatigue syndrome. The participants were allocated by chance to
receive either 14 weeks of treatment with Acclydine together with amino
acid supplements or, alternatively, placebo versions of the Acclydine and
amino acid tablets. The researchers then measured participants’
responses with respect to two primary outcome measures. One of these
was how tired participants felt, which was measured using a subscale on
a questionnaire called the Checklist Individual Strength scale (CIS-
fatigue). The other primary outcome measure was ‘‘functional impair-
ment,’’ which examines how well someone carries out their daily life,
using the Sickness Impact Profile (SIP-8) scale. The secondary outcome
measures included physical activity levels, day-to-day fatigue levels, and
the levels of insulin-like growth factor 1 (IGF1) in blood, a hormone that’s
thought by some researchers to be related to the severity of chronic
fatigue.
What the trial shows: In the trial, 57 people were randomized to receive
either Acclydine plus amino acid supplements, or placebo tablets. When
comparing scores on the primary outcome measures at the end of the
trial, the researchers did not see significant differences between the
treatment and placebo groups. Similarly, the results for secondary
outcome measures in this trial did not show any significant differences
between the treatment and placebo groups.
Strengths and limitations: Strengths of this study include the fact that
it is one of the few properly designed studies of a product for which
claims have been made of effectiveness in chronic fatigue syndrome. The
study was designed as a double-blind trial, in which participants and
investigators (those collecting the outcome data) did not know whether
an individual received Acclydine or placebo. This procedure should help
to minimize bias in assessing outcomes. A key limitation of this study is
the relatively small number of participants. However, the investigators
considered it unlikely that a larger trial would detect a clinically
meaningful effect of Acclydine on these outcome measures for patients
with chronic fatigue syndrome.
Contribution to the evidence: Systematic reviews of interventions for
the treatment of chronic fatigue syndrome have found evidence for the
efficacy of exercise therapy and cognitive behavioral therapy. This trial
shows no evidence of efficacy of Acclydine plus amino acid supplements
for the treatment of chronic fatigue.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.METHODS
The study was approved by the medical ethical committee of
the Radboud University Nijmegen Medical Centre. Written
informed consent was obtained from all participants prior to
enrollment.
Participants
Patients were recruited through the outpatient clinic of the
Department of General Internal Medicine of the Radboud
University Nijmegen Medical Centre and through an adver-
tisement in the newsletter of the Dutch CFS patient
organization ME-Stichting (http://www.me-cvs-stichting.nl).
Patients were eligible for participation if they fulﬁlled the
following inclusion criteria: they had to be between 18 and 65
y of age, and they had to fulﬁll the CDC consensus criteria for
CFS [1]. A Structured Clinical Interview for DSM-IV (SCID-1)
was performed to exclude patients with current psychiatric
co-morbidity and to ensure a homogeneous group of
patients.
Pregnant or lactating women were excluded, as were
patients with lactose intolerance and patients taking psycho-
tropic drugs or experimental medications.
An additional criterion to be met was an IGFBP3/IGF1
ratio greater than 2.5. We asked patients who could
potentially participate in the trial, if possible, to bring a
healthy neighborhood control individual of similar age,
gender, body weight, and body height, to compare IGF status.
Except for contraceptives, the control individuals were not
allowed to take medication.
Interventions
Acclydine and an identical placebo were delivered by the
manufacturer Optipharma. Each Acclydine capsule con-
tained 250 mg of the alkaloid. Patients took a single daily
dose on an empty stomach, with the following decreasing
Acclydine dosage schedule over a total of 14 wk: weeks 1–2,
1,000 mg per day; weeks 3–6, 750 mg per day; weeks 7–8, 500
mg per day; weeks 9–10, 500 mg every 2 d; weeks 11–12, 250
mg per day; and weeks 13–14, 250 mg every 2 d.
Acclydine treatment was combined with amino acid
supplements to provide sufﬁcient essential and nonessential
amino acid intake during treatment. Patients in the placebo
group received placebo Acclydine and placebo amino acid
supplements.
There was no difference in taste, appearance, or packaging
between the active supplements and the placebo capsules.
Design and Procedures
The study was a prospective, randomized, double-blind,
placebo-controlled trial. The effect of Acclydine was assessed
by pre- and post-trial testing. Post-trial testing was performed
at the end of the 14-wk treatment period. During the post-trial
assessments, the patients were still taking the trial supple-
ments. All participants, investigators, and laboratory techni-
cians were blinded to the treatment condition. IGF1 and
IGFBP3 measurements were also done in a blinded fashion.
Randomization
Before the start of the clinical trial, the pharmacy of the
hospital prepared 57 treatment packages. Randomization and
allocation to the treatment or placebo group was based on a
patient’s study number. After acceptance of a patient by the
junior researcher (G. K. H. T.) and the clinical psychologist
(G. B.), the eligible patient received the lowest study number
available (1–57). The pharmacy held the randomization list
that correlated the study number with the treatment group.
To maintain balance over time, the concealed randomization
was done in blocks of ten. Treatments were generated
randomly within the blocks using a computer program (Excel,
Microsoft, http://www.microsoft.com).
Primary Outcome Measures
Fatigue severity. The Checklist Individual Strength is a
reliable and validated self-report questionnaire. We used the
Checklist Individual Strength, subscale fatigue severity (CIS-
fatigue) [15,16]. The score on this eight-item scale ranges
from eight (no fatigue) to 56 (maximally fatigued). The cut-off
point was set at 35 [17].
Functional impairment. The Sickness Impact Proﬁle-8 (SIP-
8) measures the inﬂuence of symptoms on daily functioning,
using the following eight subscales to rate both physical and
psychological disability: home management, mobility, alert-
ness behavior, sleep/rest, ambulation, social interactions,
work, and recreation and pastimes [18,19]. CFS patients with
substantial functional impairments were included. Patients
with scores above the cut-off point of 800 were included.
Secondary Outcome Measures
Activity level. Besides self-reported outcome measures, we
measured physical activity with an actometer. An actometer is
a small motion-sensing device attached to the ankle; it was
worn continuously for 14 d during the assessment periods.
After the 2-wk period, the average score over 12 d was
computed [20].
Daily fatigue level. During the 2-wk actometer period,
patients rated their fatigue level in a complaint diary. They
rated their level of fatigue four times a day on a zero (no
fatigue) to four (maximally fatigued) scale. The four scores for
each day were summed to produce the daily observed fatigue
(DOF) score, which ranged from 0 to 16 [21]. The mean of 12
consecutive DOF scores was used.
Blood Samples
Blood samples of the patients and the matched neighborhood
controls were taken at the same time, and the paired blinded
samples were handled in an identical fashion. Serum IGF1
was measured by an immune radiometric assay (Diagnostic
Systems Laboratories, http://www.dslabs.com). For IGF1, the
inter- and intra-assay coefﬁcients of variation were 6.25%
and 4.93%, respectively. IGFBP3 was also assessed by an
immune radiometric assay (Immulite, DPC, http://dpcweb.
com). For IGFBP3, the inter- and intra-assay coefﬁcients of
variation were 4.25% and 1.3%, respectively.
Statistical Methods
For all analyses SPSS 12.01 (SPSS, http://www.spss.com) was
used.
Power calculations before the start of the trial showed that
22 persons were needed in each group to detect a difference
of at least one standard deviation (SD) on the CIS-fatigue with
a power of 90% and a two-tailed signiﬁcance level of 5%.
Anticipating a dropout rate of 10%, at least 49 persons
needed to be recruited. Analyses were performed on an
intention-to-treat basis.
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carried forward. Independent sample t-tests were performed
on the change scores, deﬁned as the difference between
baseline scores and the post-treatment scores after 14 wk.
IGF data are given as mean 6 SD. The hormonal
measurements were analyzed by independent sample t-test.
RESULTS
All patients were recruited between February 2003 and April
2005.
In total, 22 patients were able to bring a neighborhood
control individual (four men and 18 women). The results of
the hormonal assessments are shown in Table 1. Hormonal
values including the CFS patients of the outpatient clinic and
patients who did not meet the hormonal inclusion criteria for
participation in the clinical trial are reported.
No signiﬁcant differences were found in the IGF status of
the CFS patients versus the controls.
Figure 1 illustrates participant ﬂow through the trial. In
total, 112 patients were given information about the study
protocol; 31 persons refused to participate, and the main
reason given for refusal was the intensity of the study. Data
obtained from 26 of the 31 persons who chose not to
participate showed no signiﬁcant difference in age, number
of CDC symptoms, fatigue severity, or functional impairment
between the CFS patients participating in the clinical trial
and those who chose not to participate (data not shown).
Twenty-four patients did not meet the inclusion criteria. A
total of 57 patients were randomized in the clinical trial: 15
patients were recruited from the outpatient clinic, and 42
.......................................................................................................................................................................................
Table 1. Hormonal Blood Levels
Hormone Patients (n ¼ 22) Controls (n ¼ 22) p-Value (95% CI)
Mean (SD) Range (nm/l) Mean (SD) Range (nm/l)
IGF1 (nm/l) 37.0 (19.7) 18.6–96.1 36.9 (14.1) 18.6–76.1 0.98 ( 10.3 to 10.6)
IGFBP3 (nm/l) 117.6 (60.1) 51.1–224.7 114.5 ( 54.7) 56.0–240.8 0.86 ( 31.8 to 38.1)
Ratio IGFBP3/IGF1 3.7 (2.3) 0.89–9.24 3.5 (2.3) 1.37–9.84 0.82 ( 1.2 to 1.5)
doi:10.1371/journal.pctr.0020019.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. CONSORT Flowchart
doi:10.1371/journal.pctr.0020019.g001
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organization newsletter. One patient in each arm dropped out
after randomization, and as a consequence, in each arm,
baseline data for one patient was carried forward, and a
sensitivityanalysiswasnotrequired.TheAcclydineandplacebo
treatments were well tolerated. No important side effects were
reported in either group. The Acclydine and placebo groups
did not differ with respect to age, gender, fatigue severity,
impairment, or number of CDC symptoms (Table 2).
Primary Outcomes
No signiﬁcant differences in change scores were found
between the treatment and placebo groups on the primary
outcome measures (Table 3). The CFS patients treated with
Acclydine did not show a signiﬁcant decrease in fatigue
severity (CIS-fatigue þ1.1 [95% CI  4.4 to þ6.5, p ¼ 0.70]) or
functional impairment (SIP-8þ59.1 [95% CI 201.7 toþ319.8,
p ¼ 0.65]) compared to the placebo group.
Secondary Outcomes
Actometer activity scores did not show signiﬁcant differences
between the two groups. Analysis of fatigue severity rated
with the DOF did not show signiﬁcant differences either.
No signiﬁcant differences were found between the treat-
ment and placebo groups in IGF1 blood level, IBFBP3 blood
level, or IGFBP3/IGF1 ratio at baseline; after 4, 8, or 14 wk of
treatment; or during follow-up (Figure 2).
DISCUSSION
Interpretation
In this randomized controlled blinded clinical trial, no
therapeutic effect of Acclydine in CFS was found. In this study
wealsoaddressedtheissueofadeﬁciencyofbioactiveIGF1.To
control for unwanted stress effects and other confounders, the
blood samples were taken simultaneously from the patients
and their matched neighborhood controls. For each pair of
patient and control, the measurements of IGF1 and IGFBP3
were performed in the same run. In addition, we detected no
differences in IGF1 or IGFBP3 concentrations in CFS patients
without psychiatric co-morbidity versus closely matched
healthy neighborhood controls.
Although the sample size is relatively small, the results do
not point to a different IGFBP3/IGF1 status in CFS patients
compared to controls. These results do not support the
hypothesis that changes in IGF1 and IGFBP3 metabolism are
involved in the pathophysiology of CFS.
Generalizability
In this study we enrolled a representative sample of adult
referred and non-referred CFS patients who fulﬁlled the
international CDC consensus criteria for CFS [1]. In contrast
to previous intervention studies with cognitive behavioral
therapy [22] or with a polynutrient supplement [23] con-
ducted by our research group, we excluded patients with
psychiatric co-morbidity to exclude hormonal inﬂuences
caused by current psychiatric co-morbidity. The mean fatigue
severity and functional impairment scores in this study
represent high fatigue severity levels and high functional
impairment in the CFS patients. Compared to the previously
mentioned intervention studies, the patients in this clinical
trial reported slightly lower fatigue and functional impair-
ment scores. Selection of CFS patients without current
psychiatric co-morbidity could explain this difference.
.......................................................................................
Table 2. Patient Characteristics
Characteristic Acclydine Group
(n ¼ 30)
Placebo Group
(n ¼ 27)
Age, years 40.9 (9.4) 43.4 (11.2)
Female 77% 59%
CIS-fatigue 46.5 (7.4) 46.2 (7.9)
SIP-8 1,484 (520.4) 1,317 (481.7)
CDC symptoms 7.6 (1.4) 7.5 (1.3)
Values are mean (SD), except for gender, which is given as percent female.
doi:10.1371/journal.pctr.0020019.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 3. Treatment Effect
Outcomes Evaluation Group
a Baseline
b At 14 wk
b Treatment Effect (95% CI) p-Value
Primary CIS-fatigue Acclydine 46.5 (7.4) 42.4 (11.6) 1.1 ( 4.4 to 6.5) 0.70
Placebo 46.2 (7.9) 43.0 (12.6)
SIP-8 Acclydine 1,484.0 (520.4) 1,228.1 (619.7) 59.1 ( 201.7 to 319.8) 0.65
Placebo 1,317.0 (481.7) 1,120.2 (543.0)
Secondary Actometer Acclydine 60.8 (20.5) 64.9 (23.4) 4.1 ( 5.9 to 14.0) 0.42
Placebo 64.8 (25.2) 64.9 (23.5)
DOF Acclydine 8.6 (2.3) 8.0 (2.8)  0.2 ( 1.2 to 0.9) 0.76
Placebo 7.7 (2.2) 7.0 (2.6)
IGF1 Acclydine 43.2 (32.1) 37.7 (22.0)  4.6 ( 17.7 to 8.6) 0.49
Placebo 37.3 (18.0) 36.3 (18.8)
IGFBP3 Acclydine 163.4 (34.1) 160.6 (32.9)  1.7 ( 17.5 to 14.0) 0.83
Placebo 168.9 (39.6) 164.3 (29.5)
IGFBP3/IGF1 ratio Acclydine 5.3 (3.7) 5.7 (3.2)  0.5 ( 2.8 to 1.7)) 0.63
Placebo 5.6 (3.1) 5.4 (2.1)
aAcclydine group, n ¼ 30; placebo group, n ¼ 27.
bValues are mean (SD).
A decline in CIS-fatigue, SIP-8, DOF scores, IGFBP3 scores or the IGFBP3/IGF1 ratio is considered a positive outcome, i.e., an improvement. A decline in actometer, IGF1, is considered a
negative outcome. The treatment effect is considered positive when the improvement in the Acclydine group is larger than that of the placebo group.
doi:10.1371/journal.pctr.0020019.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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To our knowledge, this is the ﬁrst published report of a
randomized controlled trial evaluating the effect of the food
supplement Acclydine in CFS patients. The effect was
assessed by pre- and post-trial testing with validated instru-
ments designed to assess different dimensions of CFS as well
as treatment effects. Treatment with Acclydine was not more
effective than placebo in changing self-reported outcome
measures, hormonal blood levels, or physical activity.
The lack of signiﬁcant differences on any of the dimensions
of fatigue or the hormonal assessments strengthens our
overall ﬁndings.
Previous unpublished studies by others on ﬁle at the
manufacturer claimed that treatment with Acclydine would
be more effective in CFS patients with a higher IGFBP3/IGF1
ratio. Based on this claim, we did a subset analysis for patients
with a ratio greater than 4.5:19 CFS patients in the Acclydine
group and 20 in the placebo group had a ratio greater than
4.5. No signiﬁcant differences in change scores were seen
between the subgroups in any of the outcome measures.
A second claim was that Acclydine treatment works by
increasing biologically active IGF1. However, assessment of
IGF1 concentration and IGFBP3/IGF1 values in the Acclydine
group at baseline, 4 wk, and 8 wk during treatment, at the end
of treatment, and at follow-up (1 mo after the treatment
period) did not show a signiﬁcant change.
The power of our study was sufﬁcient to detect changes in
time in both groups. Thus, the negative ﬁndings found in this
randomized controlled trial cannot be explained by a power
problem. Considering the reported treatment effect on the
primary outcome measures, we believe it is very unlikely that
a larger trial would detect a clinically meaningful effect.
It is of interest to note that we detected a minor placebo
effect in this study. This is in accordance with observations
from earlier randomized controlled clinical trials in CFS [23–
25]. However, the minimal decline in fatigue severity and
functional impairment during pre- and post-trial testing in
both treatment groups could also be partly explained by the
phenomenon regression to the mean or a Hawthorne effect.
We did not monitor patient compliance on a daily basis.
During the trial, patients had an appointment by telephone
or at the outpatient clinic every 2 wk. During these appoint-
ments, we assessed whether the capsules were taken as
directed, and the treatment protocol for the next 2 wk was
discussed with the patient. Although adherence could not be
Figure 2. Hormone Data of the Two Treatment Groups
(A) IGF1 concentration.
(B) IGFBP3 concentration.
(C) IGFBP3/IGF1 ratio.
doi:10.1371/journal.pctr.0020019.g002
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veriﬁed fully, there is no reason to believe that lack of
adherence can explain the negative ﬁndings.
In conclusion, this randomized controlled trial did not
demonstrate an effect of Acclydine on biologically active
IGF1, nor did it demonstrate any beneﬁt in CFS-related
outcome measures. Thus, the ﬁndings of this clinical trial do
not support the use of Acclydine in the treatment for CFS.
We feel that the negative results of this trial are important
for two reasons: Acclydine is expensive, so patients might be
spending a lot of money on an ineffective treatment, and it is
also available without prescription on the Internet, making it
available to patients potentially without a doctor’s oversight.
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